The Pharmaceutical Benefits Advisory Committee has recommended that mifepristone (RU486) and another drug taken in conjunction, misoprostol, be covered by the Pharmaceutical Benefits Scheme. In the coming weeks the Government will consider the recommendation and a decision is expected to be made prior to the election. More information is available… Read More »Pharmaceutical Benefits Advisory Committee recommends mifepristone (RU486) be listed on the PBS
With an AFMW membership, experience:
Enjoy leadership development, networking & mentoring opportunities. Plus join the AFMW leadership skills database.
Become actively involved in key issues surrounding the health and wellbeing of women and children, in Australia and globally.
Automatic membership of the Medical Women’s International Association, an organisation with United Nations representation.
Special Event Access
Receive invitations to access and attend educational and social events.
Member Only Resources
Access to our members only discussion forum, directory, special updates and e-newsletters.